FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:2171-2173 December 26, 2002 Number 26 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Moake, J. L. PubMed Citation

To the Editor: We write to address several statements in Dr. Moake's review of thrombotic microangiopathies (Aug. 22 issue).¹ First, assays of the activity of the metalloprotease ADAMTS 13 differ in design; the normal range of activity is assay-specific.² The use of an assay for which the normal range is 79 to 127 percent, rather than 50 to 178 percent, as cited by Moake, permitted the identification of carriers of ADAMTS 13 mutations (45 to 68 percent activity) and linked the defect to the ADAMTS 13 gene.³ We urge caution in comparing the results of different assays.

Also, the identity . . . [Full Text of this Article]

This article has been cited by other articles:

• Rasko, D. A., Moreira, C. G., Li, D. R., Reading, N. C., Ritchie, J. M., Waldor, M. K., Williams, N., Taussig, R., Wei, S., Roth, M., Hughes, D. T., Huntley, J. F., Fina, M. W., Falck, J. R., Sperandio, V. (2008). Targeting QseC Signaling and Virulence for Antibiotic Development. Science 321: 1078-1080 [Abstract] [Full Text]